Evidence map›Paper›PMID 42035150›Full record

ArticleJournal of nanobiotechnology2026

A spatiotemporally coordinated curcumin-based microneedle patch for SDF-1α delivery and synergistic myocardial infarction therapy.

Xue-Yan Jiang, Yuan Luo, Yang Yang, Da-Wei Tang, Zhizhong Wang, Pei Huang, Fang-Zhen Wang, Shu-Meng Zhang, Hao-Min Zhang, Yi-Yun Ma and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Xue-Yan Jiang *Key Laboratory of Molecular Target & Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, the NMPA, Guangzhou Medical University, Guangzhou, 511436, China.
Yuan Luo *Key Laboratory of Molecular Target & Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, the NMPA, Guangzhou Medical University, Guangzhou, 511436, China.
Yang Yang *Key Laboratory of Molecular Target & Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, the NMPA, Guangzhou Medical University, Guangzhou, 511436, China.
Da-Wei TangKey Laboratory of Molecular Target & Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, the NMPA, Guangzhou Medical University, Guangzhou, 511436, China.
Zhizhong WangKey Laboratory of Molecular Target & Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, the NMPA, Guangzhou Medical University, Guangzhou, 511436, China.
Pei HuangKey Laboratory of Molecular Target & Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, the NMPA, Guangzhou Medical University, Guangzhou, 511436, China.
Fang-Zhen WangKey Laboratory of Molecular Target & Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, the NMPA, Guangzhou Medical University, Guangzhou, 511436, China.
Shu-Meng ZhangKey Laboratory of Molecular Target & Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, the NMPA, Guangzhou Medical University, Guangzhou, 511436, China.
Hao-Min ZhangKey Laboratory of Molecular Target & Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, the NMPA, Guangzhou Medical University, Guangzhou, 511436, China.
Yi-Yun MaKey Laboratory of Molecular Target & Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, the NMPA, Guangzhou Medical University, Guangzhou, 511436, China.
Xu-Chen LiuKey Laboratory of Molecular Target & Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, the NMPA, Guangzhou Medical University, Guangzhou, 511436, China.
Yun-Ru LiKey Laboratory of Molecular Target & Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, the NMPA, Guangzhou Medical University, Guangzhou, 511436, China.
Wenhua ZhengDepartment of Pharmaceutical Science, Faculty of Health Sciences, University of Macau, Taipa, 999078, Macau, China.
Lingmin ZhangKey Laboratory of Molecular Target & Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, the NMPA, Guangzhou Medical University, Guangzhou, 511436, China. zhanglm@gzhmu.edu.cn.
Xi-Yong YuKey Laboratory of Molecular Target & Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, the NMPA, Guangzhou Medical University, Guangzhou, 511436, China. yuxycn@gzhmu.edu.cn.
Gen HeKey Laboratory of Molecular Target & Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, the NMPA, Guangzhou Medical University, Guangzhou, 511436, China. hegen@gzhmu.edu.cn.

Funding

National Key Research and Development Program of China 2022YFE0209700National Natural Science Foundation of China 22004136Natural Science Foundation of Guangdong Province 2021A1515011950Project of Educational Commission of Guangdong Province of China 2024KTSCX119Project of Guangzhou Education Bureau 2024312127Science and Technology Program of Guangzhou 2024A04J5070
6 · The paper itself

Abstract

introductionEffective myocardial regeneration following infarction remains a major clinical challenge due to the complex and dynamic pathological microenvironment. Current clinical management fails to adequately modulate the dynamic infarct microenvironment, where dysregulated inflammation and insufficient angiogenesis represent key therapeutic targets.

methodsTo address this challenge, we developed a spatiotemporally coordinated microneedle (MN) patch based on curcumin-conjugated gelatin methacrylate (Cur-GelMA) hydrogel for co-delivery of curcumin and stromal cell-derived factor-1α (SDF-1α).

resultsThe engineered Cur-GelMA network significantly enhanced curcumin solubility and bioavailability, while PDMS micromolding enabled fabrication of mechanically robust MN patches. This integrated system provides rapid, reactive oxygen species-responsive curcumin release along with sustained SDF-1α delivery, achieving spatially targeted penetration and localized drug deposition in the infarcted myocardium. In vitro studies demonstrated that curcumin-hydrogel effectively reprogrammed macrophage polarization from pro-inflammatory M1 to reparative M2 phenotype, downregulating pro-inflammatory cytokines while upregulating anti-inflammatory cytokine. Simultaneously, sustained SDF-1α release promoted endothelial cell proliferation, migration, and tube formation via VEGF pathway activation. In a rat MI model, the SDF-1α@Cur-MN patch significantly improved recovery of cardiac function, attenuated fibrosis, enhanced M2 macrophage infiltration, and promoted mature neovessel formation.

conclusionThis dual-target MN system provides a coordinated approach to regulating inflammation and angiogenesis, demonstrating therapeutic potential for myocardial repair.

Indexed as

Chemokine CXCL12CurcuminMyocardial InfarctionAnimalsCell ProliferationHumansHydrogelsMacrophagesMaleMicroneedle Drug DeliveryRatsRats, Sprague-DawleyChemokine CXCL12CurcuminHydrogelsAngiogenesisCurcuminMacrophage ReprogrammingMicroneedle PatchMyocardial InfarctionSDF-1α

Identifiers

PMID42035150
PMCPMC13273951

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.